A Clincal Trial of Apatinib Mesylate and Etoposide(VP-16) as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy
Latest Information Update: 03 Dec 2019
At a glance
- Drugs Etoposide (Primary) ; Rivoceranib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 03 Dec 2019 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified December 2017).
- 05 Dec 2017 Planned End Date changed from 1 May 2018 to 1 Dec 2018.
- 05 Dec 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.